This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- PROTEUS (NCT03767244) is a phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of 12 cycles of perioperative treatment with ERLEADA plus androgen deprivation therapy (ADT; n=1057) compared with placebo plus ADT (n=1052) in patients with newly diagnosed localized or locally advanced high-risk prostate cancer undergoing radical prostatectomy (RP) with pelvic lymph-node dissection (N=2109). The dual primary endpoints are a composite endpoint of pathological complete response (pCR) or minimal residual disease (MRD) and metastasis-free survival (MFS), based on conventional or prostate-specific membrane antigen positron-emission tomography (PSMA-PET) imaging. Both endpoints were assessed by blinded independent central review (BICR).1-3 An infographic is available that provides a summary of the study design, efficacy, and safety results.
- After a median follow-up of 61.7 months, the percentage of patients with a pCR or MRD was significantly higher in the ERLEADA group vs the placebo group (8.9% vs 1.0%; odds ratio [OR], 10.17; 95% confidence interval [CI], 5.27-19.64; P<0.001) as well as probability of MFS at 5 years (78.2% vs. 73.5%; hazard ratio [HR], 0.80; 95% CI, 0.67-0.96; P=0.02).
- Any adverse event (AE) occurred in 98.8% vs 97.8% of patients in the ERLEADA group vs placebo group, with grade 3 or 4 AEs occurring in 39.6% vs 31.0%, respectively. The most common AEs in the ERLEADA group vs placebo group were: hot flush (63.4% vs 56.5%), urinary incontinence (50.2% vs 50.9%), and erectile dysfunction (41.6% vs 41.4%).
- PROTEUS Substudy: a phase 3, randomized, open-label, parallel-group substudy was also conducted to evaluate the safety and efficacy of 12 cycles of perioperative treatment with ERLEADA plus ADT plus RP (n=102) vs RP alone (n=306) in patients with high-risk localized or locally advanced prostate cancer (N=408). The substudy was conducted independently of the main study and no patients in the substudy participated in the main study. The primary endpoint is event-free survival (EFS).4 An infographic is available that provides a summary of the study design, efficacy, and safety results.
- After a median follow-up of 37.4 months in patients without EFS events, patients in the ERLEADA group had significant improvement in EFS compared with patients in the RP alone group (median not reached vs 19.1 months; estimated 3-year event-free rates were 63% vs 41%; HR, 0.38; 95% CI, 0.26–0.55; P<0.001).
- Any AE occurred in 98% vs 95% of patients in the ERLEADA group (n=101) vs RP along group group (n=286), with grade 3 or 4 AEs occurring in 31% vs 22%, respectively. The most common AEs in the ERLEADA group vs RP alone group were: hot flash (64% vs 0.70%), urinary incontinence (63% vs 66%), and erectile dysfunction (56% vs 62%).
- A post-hoc analysis of the PROTEUS main study was conducted to evaluate prostate-specific antigen (PSA) response and long-term outcomes for patients in the ERLEADA group.5 Of patients with PSA values at cycle 9, 89.3% (1634/1830) had ultra-low PSA (<0.02 ng/mL) post RP. Results included evaluation of PSA over time, long-term outcomes including MFS, EFS, time to distant metastasis (TTDM), and time to first systemic or local therapy (TTFST), and biochemical failure (BCF) status at 3 years.
CLINICAL DATA
PROTEUS Main Study
PROTEUS is a phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of ERLEADA plus ADT compared to placebo plus ADT before and after RP in patients with localized or locally advanced high-risk prostate cancer (N=2109).1
PROTEUS Substudy
PROTEUS substudy is a phase 3, randomized, open-label, multicenter. parallel-group study evaluating the safety and efficacy of ERLEADA plus ADT plus RP compared with RP alone in patients with high-risk localized or locally advanced prostate cancer (N=408).4



Post-Hoc Analysis of the PROTEUS Main Study
A post-hoc analysis was conducted to evaluate PSA response for patients in the ERLEADA group during the main study.5
At cycle 9, 89.3% (1634/1830) of patients with PSA values had ultra-low PSA post RP. Among the long-term outcomes evaluated in these patients were significant improvement at cycle 9 and post end of treatment [EOT] 3 months into follow-up as follows, respectively:
- MFS: median not reached [NR]; HR, 0.34; 95% CI, 0.25-0.46; P<0.0001 and median NR; HR, 0.33; 95% CI, 0.24-0.43; P<0.0001
- EFS: median 61.4 months; HR, 0.60; 95% CI, 0.48-0.76; P<0.0001 and median 69.4 months; HR, 0.50; 95% CI, 0.41-0.61; P<0.0001
- TTDM: median NR; HR, 0.51; 95% CI, 0.34-0.76; P=0.0009 and median NR; HR, 0.45; 95% CI, 0.31-0.63; P<0.0001
- TTFST: median 74.2 months; HR, 0.57; 95% CI, 0.45-0.74; P<0.0001 and median NR; HR, 0.56; 95% CI, 0.45-0.69; P<0.0001
When evaluating PSA over time, patients in the ERLEADA group had reduced PSA levels pre-surgery (cycle 4), with most patients experiencing ultra-low PSA levels post surgery (cycle 9) that was maintained through EOT and follow-up.
Patients in the ERLEADA group without BCF at 3 years had significantly improved MFS (median NR vs 68.3 months; HR, 0.24; 95% CI, 0.18-0.32; P<0.0001) and TTDM (median NR vs 71.3 months; HR, 0.11; 95% CI, 0.07-0.15; P<0.0001) vs those with BCF.
The median duration of ultra-low PSA in the ERLEADA group vs placebo group was 13.6 months vs 10.9 months, respectively.
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 28 October 2026.
| 1 | Taplin ME, Gleave M, Shore ND, et al. Perioperative apalutamide in high-risk localized prostate cancer. N Engl J Med. 2026;395(6):546-560. |
| 2 | Taplin ME, Gleave M, Shore ND, et al. Supplement to: Perioperative apalutamide in high-risk localized prostate cancer. N Engl J Med. 2026;395(6):546-560. |
| 3 | Taplin ME, Gleave M, Shore ND, et al. Perioperative (neoadjuvant and adjuvant) apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized or locally advanced prostate cancer: final analysis of the PROTEUS phase 3 study. Plenary session presented at: 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2026; Chicago, IL. |
| 4 | Briganti A, Steuber T, Shore ND, et al. Treatment effect of perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy versus radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer from the PROTEUS substudy. [published online ahead of print October 24, 2026]. Eur Urol. 2026. doi:10.1016/j.eururo.2026.10.016. |
| 5 | Hadaschik BA, Shore ND, Efstathiou E, et al. Prostate-specific antigen response and long-term outcomes in PROTEUS: perioperative apalutamide plus androgen deprivation therapy in patients with high-risk localized/locally advanced prostate cancer. Poster presented at: European Society for Medical Oncology (ESMO) Congress; October 23-27, 2026; Madrid, Spain. |